drugset / Trial / NCT07557602
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
RandomizedSequentialQuadruple-blindPrevention
Summary
This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Timeline
- Start
- 2026-05-04
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VXCO-102 | Messenger RNA (mRNA) | — | Intramuscular |